title: Splenectomy in cirrhosis with hypersplenism: improvement in cytopenias, Child's status and institution of specific treatment for hepatitis C with success.
abstract: BACKGROUND
  Hypersplenism in cirrhosis is not infrequent and may compromise with quality of life and therapy. Splenectomy is a therapeutic option, but information on results of splenectomy is scarce.
  
  
  METHODS
  Consecutive patients with cirrhosis who underwent splenectomy between 2001-2010 were included in the study. Safety, efficacy of splenectomy and subsequent influence on therapy were evaluated.
  
  
  RESULTS
  Thirty three patients (mean age 30.9 ± 11.6 years, 19 men, viral 48.5%, autoimmune 15.1%, cryptogenic 36.4%) underwent splenectomy. Twenty were Child's A, 13 Child's B. Twenty patients had > 6 months follow up. Common indications were inability to treat with interferon, transfusion-dependent anemia, recurrent mucosal bleeds, and large spleen compromising quality of life. Median hospital stay was 7 (4-24) days. There was no splenectomy related mortality. Twenty three (70%) patients had post-operative complications, most commonly infections. Two patients required percutaneous drainage of post-operative collections, and 1 needed re-exploration for intra-abdominal bleed. Subsequent to splenectomy platelet count (44,000 to 151,000/mm 3 , p < 0.01) and TLC (2,500 to 13,400/mm 3 , p < 0.01) had sustained increase in all patients except one. Five HCV cirrhotics completed interferon and ribavirin therapy, 4 achieved sustained viral response. The quality of life improved and there was no recurrence of infections, mucosal bleed or anemia requiring transfusions in any patient. In patients on long term follow up (median duration 27 months), the median Child's score improved from 6 at baseline to 5 at follow up (p < 0.05).
  
  
  CONCLUSIONS
  Splenectomy was safe and effective in patients with cirrhosis, and improved therapeutic options as well as Child's score.
authors.affiliation: Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India.
authors.forename: Saurabh
authors.initials: S
authors.lastname: Kedia
authors.forename: Rohit
authors.initials: R
authors.lastname: Goyal
authors.forename: Vivek
authors.initials: V
authors.lastname: Mangla
authors.forename: Ajay
authors.initials: A
authors.lastname: Kumar
authors.forename: Shalimar
authors.initials: S
authors.lastname: S
authors.forename: Prasenjit
authors.initials: P
authors.lastname: Das
authors.forename: Sujoy
authors.initials: S
authors.lastname: Pal
authors.forename: Peush
authors.initials: P
authors.lastname: Sahni
authors.forename: Subrat K
authors.initials: SK
authors.lastname: Acharya
mesh_terms: D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006526:Hepatitis C / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D006971:Hypersplenism / Q000175:diagnosis / Q000601:surgery* / Q000821:virology; D007372:Interferons / Q000627:therapeutic use*; D007902:Length of Stay; D007970:Leukopenia / Q000175:diagnosis / Q000628:therapy* / Q000821:virology; D008103:Liver Cirrhosis / Q000175:diagnosis / Q000628:therapy* / Q000821:virology; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000209:etiology / Q000628:therapy; D011788:Quality of Life; D012254:Ribavirin / Q000627:therapeutic use*; D013156:Splenectomy / Q000009:adverse effects; D013921:Thrombocytopenia / Q000175:diagnosis / Q000628:therapy* / Q000821:virology; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons